Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer.

Merel van NulandAndries M BergmanHilde RosingNiels de VriesAlwin D R HuitemaJos H Beijnen

Published in: Pharmacotherapy (2019)

This study confirmed that enzalutamide plasma concentrations were not related to PSA-independent PFS, TTPP, or toxicity in patients with mCRPC, and demonstrated that plasma concentrations of its major metabolites were also not associated with treatment response. Based on these findings, there is no role for therapeutic drug monitoring of enzalutamide in patients with mCRPC in daily practice.

Keyphrases

prostate cancer
radical prostatectomy
ms ms
healthcare
primary care
oxidative stress
physical activity
drug induced